Bio-Rad to acquire Stilla Technologies.

Bio-Rad Laboratories, an American life science research and clinical diagnostics technological products developer and manufacturer, agreed to acquire Stilla Technologies, digital PCR solutions provider. Financial terms were not disclosed. "Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio. Once closed, the acquisition will support our strategy to further expand our business into applied research and clinical diagnostics where customers expect a higher degree of automation and throughput capabilities,” Norman Schwartz, Bio-Rad Laboratories CEO.